| Literature DB >> 34945704 |
Leidy Johana Valencia-Hernandez1, Jorge E Wong-Paz2, Juan Alberto Ascacio-Valdés1, Mónica L Chávez-González1, Juan Carlos Contreras-Esquivel1, Cristóbal N Aguilar1.
Abstract
Procyanidins are an important group of bioactive molecules known for their benefits to human health. These compounds are promising in the treatment of chronic metabolic diseases such as cancer, diabetes, and cardiovascular disease, as they prevent cell damage related to oxidative stress. It is necessary to study effective extraction methods for the recovery of these components. In this review, advances in the recovery of procyanidins from agro-industrial wastes are presented, which are obtained through ultrasound-assisted extraction, microwave-assisted extraction, supercritical fluid extraction, pressurized fluid extraction and subcritical water extraction. Current trends focus on the extraction of procyanidins from seeds, peels, pomaces, leaves and bark in agro-industrial wastes, which are extracted by ultrasound. Some techniques have been coupled with environmentally friendly techniques. There are few studies focused on the extraction and evaluation of biological activities of procyanidins. The identification and quantification of these compounds are the result of the study of the polyphenolic profile of plant sources. Antioxidant, antibiotic, and anti-inflammatory activity are presented as the biological properties of greatest interest. Agro-industrial wastes can be an economical and easily accessible source for the extraction of procyanidins.Entities:
Keywords: agro-industrial waste; bioactive; extraction process; procyanidins
Year: 2021 PMID: 34945704 PMCID: PMC8701411 DOI: 10.3390/foods10123152
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Structure of A1-type dimer procyanidins linked with double C4 → C8 and C2-O-C7 linkage.
Figure 2Structure of B1-type dimer procyanidin linked with a single C4 → C8.
Sources of procyanidins from agro-industrial wastes.
| Plant | Waste Type | Compound Type | Concentration | Reference |
|---|---|---|---|---|
| Peel | PCB | - | [ | |
|
| PCB2 | 390 mg/g extract | [ | |
| C, EC, | - | [ | ||
|
| PCs: dimers and trimers | - | [ | |
|
| Pericarp | PCs: A and B | - | [ |
| PCO | - | [ | ||
| Pomace | PCs: B1, B2 | 4.8–4.3 ug/kg extract | [ | |
|
| Leaf | PCB2 | 13.4 ug/mL | [ |
|
| PCB | - | [ | |
|
| EC, PCs: B2, B5, C1, D1 | - | [ | |
|
| PCB7 (dimer) | - | [ | |
|
| EC, PCA2 | 14.8–44.5 and 44.8–69.6 mg/g extract | [ | |
| PCs | - | [ | ||
| PCs | - | [ | ||
| Leaf and stem | EC and PCB2, respectively | - | [ | |
| C, PCs: A, B, dimers, trimers | - | [ | ||
| Crataegus spp | Leaf and flower | PCO | - | [ |
|
| Flower | PCA | [ | |
|
| PCO | - | [ | |
| PCs | - | [ | ||
|
| PCs | - | [ | |
| Seed | PCB2 | 0.41–1.6 mg/g | [ | |
|
| PCs: B1, B3, B6, B4, B2, B7, B5 | - | [ | |
| PCs | - | [ | ||
|
| C, EC, PCB1 | - | [ | |
| Seed and peel | PCP | 1189.76–2631.73 mg/100 g | [ | |
|
| Bark | PCs: A, B | - | [ |
|
| PCs: B2, B5, C1 | - | [ | |
| C, EC, PCs: B, C. | - | [ | ||
|
| CT | 841 mg/g extract | [ | |
| Wood | PCB2 | - | [ | |
|
| Stem and root | PCB2 | - | [ |
|
| Pulp | PCs: B2, A (trimer), C1, tetramer, pentamer, | - | [ |
| Hulls | PCs: B1, B2 | 0.55–0.83 and 0.23–0.9 mg/g | [ | |
|
| Aerial parts | PCB | - | [ |
|
| Ripe and over-ripe pears | PCs (low DP) | - | [ |
Biological activity of procyanidins obtained from agro-industrial wastes, and possible applications.
| Agro-Industrial Waste | Procyanidin Type | Application Potential/Attributes | Assay | Biological Activity | Reference |
|---|---|---|---|---|---|
|
| PCA2 | Control programs of | In Vitro | Anthelmintic activity in larval | [ |
| PCA (commercial compound of Indus Biotech Private Limited, Pune, India) | - | In Vivo (animals) | Anti-allergic | [ | |
| PCC4 and cinnamtannin D1 | Development of pharmaceutical products | In Vitro | Antibacterial, and pleiotropic effects | [ | |
| PCs: dimer B1 and trimer C2 | Functional cosmetic | In Vitro | Antioxidant and anti-wrinkles | [ | |
| C, EC, dimer A, dimer B1, dimer B2, dimer B3, trimer A | - | In Vitro | Antioxidant, inhibition of α-glucosidase activity, lipase activity, LDL-cholesterol oxidation | [ | |
| PC A (trimerics and pentamerics) | - | In Vitro | Anti-VIH-1 | [ | |
| PCB1 | Cancer chemoprevention, antineoplastic agent, cardiovascular benefit | In Vitro/In Vivo (animals) | Inhibition of cyclooxygenase-2 and enhance prostacyclin | [ | |
| PCB | - | In Vivo (animals) | Antithrombotic | [ | |
| Monomers, dimers, and PCO | -Ingredient in chocolate processing | In Vitro | - | [ | |
| C, EC, and PCs: trimeric A, tetrameric A, and PCP. | - | In Vitro | Anthelmintic | [ | |
| C, and PCB2 | Treatment against cancer | In Vitro | Cytotoxic effect in ovarian cancer cell, impact the regular cell cycle progression of cancer and overcoming drug resistance | [ | |
| PCO: A-type | - | In Vitro | Hypoglycemic | [ | |
| PC: dimer B | - | In Vitro | Anti-inflammatory and antioxidant | [ | |
| C, EC, and PCs: B2, trimer B, and tetramer B | - | In Vitro | Antioxidant | [ | |
| C, EC PC with DP up to the 20-mers. | Chelating ability | In Vitro | Inhibition on the melanogenic activity in B16 | [ | |
| PCA2 | Therapy of liver damage | In Vitro/In Vivo | Antioxidant | [ | |
| C, EC and PC B2 | Treatment of diabetes | In vitro | Antioxidant, hepatoprotective effect, influence glutathione reductase activity and glutathione level. | [ | |
| C, EC, and PCs: dimer B1, dimer B2, dimer B5, dimer B2 gallate, trimer C1, trimer T2, tetramer A2, unknown dimers, pentamers, and hexamers | - | In Vitro | Antimicrobial | [ | |
| C, PCs: dimer B, digalloylated PC PCB, monogalloylated procyanidin dimer B | Rapid biotransformation | In Vitro | Antioxidant | [ | |
| PCB | Treatment of Herpes simplex virus type infections | In Vitro/In Vivo (animals) | Antiviral | [ | |
| PCs | Healthcare, and cosmetic | In Vitro | Antimicrobial, affects membrane protein synthesis of | [ | |
|
| PCs | Prevention and control of | In Vitro | Antioxidant and gastroprotective activity | [ |
| Mixture of procyanidins | Treatment therapeutics | In Vitro | Antioxidant | [ | |
| PCs: dimer, trimer C1 | - | In Vitro/In Vivo (animals) | Antioxidant, enhancement of catalase and glutathione peroxidase activity in colon. | [ | |
| Juice from Unripe | C, EC and | - | In Vitro | Antioxidant and Anti-browning | [ |
| EC, and PCs: B2 and C1 | Treatments in diabetes mellitus | In Vitro | Antioxidant, inhibitory activities against advanced | [ | |
| PCB2 3,3”-di-O-gallate | Control malignant cells in prostate | In Vitro | Inhibition MAP kinase phosphatase | [ | |
| Commercial ( | PCs dimers | Potential in cardiovascular and obesity treatment | In Vivo (animals) | Reduces adiposity and oxidative stress in the heart | [ |
| Coffea arabica L. pulp | PCs: dimers and trimers | In Vitro | Anti-inflammatory and inhibition interleukin-8 release in human gastric epithelial cells | [ | |
| PCB2–8-C-rhamnoside, PCB2 (epi)-catechin—(epi)-catechin | Potential as antifatigue drug | In Vivo (animals) | Antioxidant, anticholinesterase, | [ | |
| Proanthocyanidins | Food ingredient | In Vitro | Antioxidant and antimicrobial | [ | |
| C, EC, and PCs: B1 and B2, | - | In Vitro | Antioxidant and anti-inflammatory | [ | |
| PCA2 | - | In Vitro | Hepato-protective effects | [ | |
| Stem bark of | PCB3 | Anti-breast cancer agents | In Vitro | Antioxidant, and antiproliferative effects on cancer cells | [ |
| Leaves and stem bark of | C, EC and | - | In Vitro | Anti-inflammatory and modulation of nitric oxide synthase enzyme expression | [ |
|
| C and PCB1 | Regulation of signaling pathways homeostasis | In Vitro | Antioxidant and anti-inflammatory | [ |
| PC with of epicatechin units | - | In Vitro | Antioxidant and anti-α-amylase | [ | |
| Commercial standard of Sigma-Aldrich, Merck KGaA | PCB2 | - | Inhibition of angiogenesis, fibrogenesis processes, Inhibition of proliferation and induction apoptosis of human hepatic stellate cell | [ | |
| C, EC, and PC trimer | Thermal stability | In Vitro | Antioxidant | [ | |
| Commercial of Extrasynthese (Genay, France) | PC s: A2 and B2, and cinnamtannin B-1 | Prevention of urinary tract infections | In Vitro | Antiadhesive of uropathogens | [ |
| C, EC, PCs: dimers 1, 2, B1, B2, and B5, trimers 1, 2, 3 and C1, tetramer 1, pentamer 1 and 2, hexamer 1and 2, heptamer 1 and 2, octamer, decamer, dimer gallate and dimer B2 gallate | - | In Vivo (animals) | Enhances cytokine production | [ | |
| PCA | - | In Vivo (animals) | Cytotoxic effect against colon cancer cells | [ | |
| PCC1 | - | In Vitro | Anticancer in breast | [ | |
| C, PCs: dimer B1, B2 and B3, galloyled procyanidin dimer, digalloylled PC dimer | - | In Vitro | Inhibition of acetylcholinesterase and antilipase activity | [ | |
| Residual cake of | C, EC, and PCs: B1, B2, and galloylated dimer | - | In Vitro | Antioxidant | [ |
| PCC1 | Application for neurological disorders | In vitro | Antioxidant, neuroprotective | [ | |
| Skin, seed, skin, and bunch stem of | PC tetramer (crown PC), PCO, PCP | - | In Vitro | Inhibition of amyloid-β peptide | [ |
Research on extraction of procyanidins from agro-industrial wastes, and future applications.
| Plant/Waste | Technique | Conditions * | Type de Procyanidin or Yield | Type of Application | Reference |
|---|---|---|---|---|---|
| SSE and UAE | 5 g/100 mL | - | Conservation of food | [ | |
| SSE | -Hexane 40 mL, centrifugation 10 min at 10,864× | 519.3 mg of PC/100 g DM | Nutraceutical, estimation method of PC | [ | |
| Enzymatic maceration | Pectinex (20 mL/100 kg sample), stirring 1 h at 20 °C. | -PCs: B1 (18.7 mg/mL), B2 (80.2 mg/mL), and C1 (18.7%). | Production of beverages and drinks | [ | |
| SSE | Methanol (8%)-Water. | PC (dimer) | Isolated procyanidin glycosides (rarely found in nature) | [ | |
| SSE | Acetone (50%)-water, ethanol (50%)-water, Methanol (50%)-water. | PCs: A and B | Antioxidant activity | [ | |
| High pressure solvent (HPE) | -CO2, CO2-ethanol (90:10), 3 times, 323 and 303 °C, 20.3 and 25.1 MPa, 370 and 360 min; 7.6, 13.2, and 19.1 kg/s × 105, solvent-to-solid mass ratio 28:1, 2:1, 20:1. | 19.8 % (mg CME **/mg extract × 100 dried base). | Improved extraction methodologies | [ | |
| * 1. M, 2. PLE, 3. UAE, 4. MAE | 1. Solid-solvent ratio (ethanol) 1g/1ml, stirred 1 h, room temperature. | PC (dimer), best results: MAE (ethanol or ethyl acetate). | Antioxidant activity | [ | |
| UAE | Bath power 250 W, Solute-solvent ratio 5 g/100 mL ethanol (50%), 0.5 h. | 601.94 mg PC/g bark (North orientation) | Use of wood in industrial process. | [ | |
| * 1. UAE, 2. M | 1. Ethanol-water (70:30), water-ethanol (30:70), 100% milliQwarer, Power 100 W, 30 min, room temperature in the dark. | PC A (dimers and trimers) obtained with UAE. | Food supplements | [ | |
| PLE | Solvent-to-solid ratio 1:3, 60, 70 and 90 °C, 5–50 min, 10.35 Mpa. | Yield: 0.73 mg PC B2/g dried cocoa Shell (60 °C, 50 min) | Antioxidant activity | [ | |
| SSE | Solution with 20 g of sample, water, ethanol (100%), aqueous acetone (70%), acetone (100%), aqueous ethanol (70%), and aqueous ethanol (40%), 30 min, centrifugation 6000 rpm by 10 min. | PC (dimer, trimer, tetramer, pentamer) | New phytochemical | [ | |
| MAE | Power 98 W, 24 °C, Ethanol (10 mL), extraction time 5-15 min, vegetal sample 1–2 g. | PC (trimer) | Formulations of food, chemical, pharmaceutical products | [ | |
| * 1. UAE, 2. Hydrodynamic cavitation (HC) | 1. -Hexane, 40 °C, 15 min | PC for HC | Process design | [ | |
| SSE | Hexane, methanol/acetic acid (99:1 | PC with a DP 9 | Formulations of juices | [ | |
| SSE | Ethanol/water (1:1, | PCB (dimer and tetramer) | Nutraceutical products | [ | |
| * 1. MAE, 2. SSE | 1. Power 500 W, heating rate 20 °C/min, 400 rpm, initial solid-solvent ratio 6 g/250 mL water, solid/liquid ratio 0.030, 0.045, 0.060 g/mL, extraction time 5, 15, 25 min and at 70, 85, 100 °C. | Polyphenols 35.9 mg GAE/g. | Food additives, food packaging | [ | |
| SSE | -Diethyl ether/ethyl acetate (DE/AE) (1:1, | PC B2 | Functional products | [ | |
| * 1. PLE—Ethanol | 1. 83 °C, 15 min, °C, 3 cycles. | 198.5 and 532.2 mg of proanthocyanidins/g. | Processing residue at industrial level. | [ |
* The numbers correspond to the conditions in each type of extraction described in the table. ** CME: (+)-catechin monohydrated equivalents.